The story of copyright's flagship drug presents a interesting case for stakeholders in the medicinal sector. While initially a blockbuster success, producing billions, the exclusivity lapse and the subsequent arrival of generic alternatives have significantly affected earnings. This raises questions about the ongoing sustainability of related th… Read More